Remove Communication Remove Information Remove Medication Labelling
article thumbnail

LENZ Therapeutics’ Presbyopia Treatment VIZZ Receives FDA Approval in the U.S.

PharmExec

August 1st 2025 FDA Mandates Safety Alterations to Opioid Pain Medication Labels Nicholas Jacobus FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management.

article thumbnail

FDA Mandates Major Opioid Label Revisions to Highlight Long-Term Risks

Pharmacy Times

SHOW MORE The FDA intends to update opioid labels to highlight risks of addiction, overdose, and interactions, enhancing safety in pain management practices. FDA Requires Major Changes to Opioid Pain Medication Labeling to Emphasize Risks. REFERENCES 1. Food and Drug Administration. Published 2025. 2022;71(3):1-95.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Mandates Safety Alterations to Opioid Pain Medication Labels

PharmExec

New labels will include study summaries, improved dosage warnings, and information on overdose reversal agents to enhance patient and healthcare professional awareness. SHOW MORE FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management.

article thumbnail

FDA Grants Accelerated Approval to Jazz Pharmaceuticals’ Modeyso for H3 K27M-Mutant Diffuse Midline Glioma

PharmExec

" Glioma Prevalence According to a study published in The National Center for Biotechnology Information, there are approximately six cases of gliomas diagnosed per every 100,000 people in the United States.

article thumbnail

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

PharmExec

Related Videos Related Content Advertisement August 1st 2025 FDA Mandates Safety Alterations to Opioid Pain Medication Labels Nicholas Jacobus FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management. Subscribe Now!

article thumbnail

President Trump Warns of 250% Tariffs While Industry Continues to React to MFN Order

PharmExec

News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Conferences Conference Coverage Conference Listing Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe Choose Specialty Corporate (..)

article thumbnail

HHS Announces Reduction in mRNA Vaccine Development Programs Under BARDA, Nearly $500 Million in Contracts Cancelled

PharmExec

News News Academy Multimedia Editorial Podcasts Editorial Videos Peer Exchange Profiles in Medicine Conferences Conference Coverage Conference Listing Publications Pharmaceutical Executive Partner Perspectives Resources Content Engagement Hubs E-Books Events Sponsored Podcasts Sponsored Videos Webcasts Whitepapers Subscribe Choose Specialty Corporate (..)